Rigel Pharma (RIGL), Aclaris Enter License Agreement for JAK Inhibitors
Tweet Send to a Friend
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Aclaris Therapeutics International Limited (ATIL), a wholly owned subsidiary of Aclaris Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE